General presentation of Vir Biotechnology
To understand the factors and events related to the market that could influence the Vir Biotechnology share price it is of course also necessary to be knowledgeable about this company and its sources of revenue. This information is what we shall now provide.
Vir Biotechnology is an American group specialised in the biotechnology sector. More precisely this company specialises in clinical stage immunology. This means it concentrates mainly on the development of treatments for the care and prevention of severe infectious diseases.
The Vir Biotechnology Group operates several technological platforms relating to anti-bodies, T cells, innate immunity, and small interference ribonucleic acids or siRNAs.
The group’s pipeline is also composed of product candidates that target hepatitis B or HBV, A type influenza, HIV or the Human Immunodeficiency virus, and tuberculosis or TB.
The candidate products on which the company is currently working are the VIR-2218, VIR-3434, VIR-2482, VIR-1111 and the VIR-2020. The company is developing VIR-2218 and VIR-3434 for the functional healing of HBV.
The VIR-2218 is notably an siRNA which targets HBV and is administered subcutaneously. The VIR-3434 is a monoclonal antibody that neutralises HBV and is administered subcutaneously. VIR-2482 is a monoclonal antibody that neutralises influenza type A and is administered intramuscularly. VIR-1111 is a T cell vaccine against HIV that is administered subcutaneously. And finally, VIR-2020 is a T cell vaccine against tuberculosis administered subcutaneously.
At present Vir Biotechnology employs nearly 330 people.